Aptazymes are small, ligand-dependent self-cleaving ribozymes that function independently of transcription factors and can be customized for induction by various small molecules. Here, we introduce these artificial riboswitches for regulation of DNA and RNA viruses. We hypothesize that they represent universally applicable tools for studying viral gene functions and for applications as a safety switch for oncolytic and live vaccine viruses. Our study shows that the insertion of artificial aptazymes into the adenoviral immediate early gene E1A enables small-molecule-triggered, dosedependent inhibition of gene expression. Aptazyme-mediated shutdown of E1A expression translates into inhibition of adenoviral genome replication, infectious particle production, and cytotoxicity/ oncolysis. These results provide proof of concept for the aptazyme approach for effective control of biological outcomes in eukaryotic systems, specifically in virus infections. Importantly, we also demonstrate aptazyme-dependent regulation of measles virus fusion protein expression, translating into potent reduction of progeny infectivity and virus spread. This not only establishes functionality of aptazymes in fully cytoplasmic genetic systems, but also implicates general feasibility of this strategy for application in viruses with either DNA or RNA genomes. Our study implies that gene regulation by artificial riboswitches may be an appealing alternative to Tet-and other protein-dependent gene regulation systems, based on their small size, RNA-intrinsic mode of action, and flexibility of the inducing molecule. Future applications range from gene analysis in basic research to medicine, for example as a safety switch for new generations of efficiency-enhanced oncolytic viruses.
U niversally applicable, cis acting and simple genetic switches implementing small molecule mediated control of viral gene expression would represent powerful tools for studying vi rus genetics in cell culture and in the host as well as for de veloping safe oncolytic viruses and virus vaccines. For analyses of viral gene functions, the insertion of such small molecule trig gered switches should enable conditional knockdown of viral genes in vitro and in vivo with superior efficiency, timing, and systemic activity as well as less off target effects compared with gene knockdown by RNA interference (RNAi). By now, the required genetic engineering methods for insertion of such cis acting switches into virus genes have become available for most viruses. In the context of therapeutic applications, replication competent viruses used for tumor destruction would benefit from genetic safety switches. Such oncolytic viruses originate from increasing numbers of virus families and results of current late stage efficacy trials fuel the rising clinical interest in the field (1) . Although safety in patients has been convincingly shown for current viruses, successful translation into clinical routine will depend on oncolytic viruses with increased potency and/or applications of viruses at higher titers. Therefore, safety will be of increasing concern. However, antiviral drugs enabling virus control in case of emerging side effects during treatment are available for very few viruses only. Thus, a drug inducible safety switch is a valuable tool to facilitate therapeutic applications of virus strains for which pathogenicity is of concern (refs. 2, 3, and references therein) and of new generations of oncolytic viruses that were engineered for enhanced potency by different strategies for which side effects in patients cannot be predicted (1, 4) . Fur thermore, transient immunosuppression is being investigated as a means to block antiviral immunity thereby enhancing oncolysis (5) . However, this strategy bears an increased risk of uncontrolled virus replication, which makes a drug triggered genetic safety switch desirable as a clinical countermeasure. Likewise, such genetic safety switches could also be used for new generations of live virus vaccines with increased safety.
Ideally, ligand inducible gene switches should be of short se quence, universally applicable in both DNA and RNA viruses, remain functional at high copy numbers after viral genome replication, and possess a simple mode of action independent of complex protein nucleic acid interactions. Here, we propose artificial riboswitches known as aptazymes as powerful genetic switches. Aptazymes consist of a self cleaving ribozyme sequence linked to a ligand binding aptamer domain (6, 7) . Hence, they enable conditional cleavage of RNA, including mRNAs, and fulfill all of the above mentioned criteria. Moreover, they can be engineered for ON or OFF switch activity by modification of the aptamer ribozyme linking sequences (8 10) . Compared with well established inducible promoters, as used for example in the Tet system (11) , aptazymes are much smaller (approximately 100 bp) and do not require the expression of recombinant, poten Significance Riboswitches are short RNA sequences for ligand-dependent modulation of gene expression in cis. This study demonstrates that an artificial riboswitch, a ligand-dependent self-cleaving ribozyme (aptazyme), can knockdown expression of an adeno-(DNA) virus early and a measles (RNA) virus structural gene, impacting biological outcomes, i.e. inhibiting viral genome replication and infectivity, respectively. It is the first report of riboswitches for replication control of human-pathogenic viruses and of their function in fully cytoplasmic (virus) systems. For future applications, aptazymes can be customized in other viruses facilitating analyses of viral gene functions or as a safety switch in oncolytic viruses. Because of their small size and RNA-intrinsic activity, we propose aptazymes as an alternative for inducible promoters in eukaryotic gene expression control.
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tially immunogenic transcription factors. Furthermore, they can be customized for responsiveness to different small molecule ligands by exchange of the aptamer domain (12, 13) . Impor tantly, due to their RNA intrinsic mode of action they should be applicable in both DNA and RNA viruses. Moreover, inducible promoters, but not aptazymes, were reported to lose regulation at high copy numbers and during DNA virus replication (14 17) , likely resulting from imbalances of stoichiometry of the required protein DNA interactions. Aptamers alone were reported to enable virus control by ligand dependent modulation of regula tory elements, as shown for a tomato virus (18) . However, this strategy has to be optimized individually for the selected virus genome context and will likely not be applicable for most viruses. In contrast, aptazymes can be universally applied by insertion into the untranslated region (UTR) of the viral target gene, enabling direct regulation of mRNA stability and translation.
Aptazymes have been extensively developed and studied in vitro, in bacteria, and in yeast (6, 12, 13, 19 22) . Their applica tion in mammalian systems, however, has been challenging. This is mostly because aptazymes selected in vitro, in bacteria, or in yeast showed loss or strong reduction of regulation when applied in mammalian cells (20, 22 24) . Previous reports on aptazyme applications in mammalian cells were reporter gene studies or studies on regulation of therapeutic gene expression (17, 23, 25, 26) .
In this study, we investigated the utility of aptazymes as tools for conditional shutdown of viral gene expression in the bi ological context of virus replication control. Specifically, we an alyzed aptazyme regulation of the immediate early gene E1A of adenoviruses and of the gene encoding the fusion glycoprotein F of measles viruses (MVs) and investigated how regulation of these genes translated into control of viral replication, infectivity, spread, and cytotoxicity. We chose adenovirus and measles virus because (i) this allowed us to explore aptazyme activity in the context of DNA viruses replicating in the nucleus and RNA viruses replicating in the cytoplasm, respectively; (ii) both viruses are being developed as oncolytic agents in preclinical and clinical studies (1); and (iii) antivirals effective in patients are not available for either virus.
Results
Aptazyme Insertion into the Adenoviral Immediate Early Gene E1A Enables Ligand-Dependent Shutdown of E1A Expression and Viral DNA Replication. Our first aim was to establish aptazyme regula tion of a DNA virus early gene enabling ligand inducible shut down of virus replication. We used human adenovirus serotype 5, a popular oncolytic agent, as model DNA virus (Fig. 1A) and inserted the OFF switch aptazyme P1 F5 (23) into the viral E1A gene. The adenoviral immediate early E1A proteins play a key role in initiating virus infection as they induce transcription of further early viral genes and modify several host cell functions, both of which are required for viral DNA replication (27) . P1 F5 possessed the best fold induction rate at the time this study was initiated, which was between three and sixfold in reporter assays (17, 23) . We hypothesized that insertion of this aptazyme into the E1A gene would not affect virus replication in the absence of the P1 F5 activating ligand theophylline (theo). Upon its addi tion, the ligand should trigger activation of the aptazyme's self cleaving activity, resulting in degradation of E1A mRNA, in hibition of E1A protein expression, and ultimately inhibition of virus genome replication (Fig. 1B and Fig. S1A ). We inserted the aptazyme (Az viruses) into the 5′ and/or 3′ UTR of the mutant E1A gene E1AΔ24 ( Fig. 2A) , commonly used in oncolytic ade noviruses because it attenuates viral replication in normal qui escent, but not tumor cells (28, 29) . As reference, matching viruses were generated containing the constitutively active ribo zyme (Rz viruses) instead of the aptazyme. A control virus contained unmodified E1A UTRs.
All viruses could be produced to normal titers in E1 com plementing cells, showed similar infectivity in these cells, and were used for infection studies in the melanoma cell line SK MEL 28. Protein expression analysis showed that ribozyme insertion abro gates E1A expression independently of both insertion site and theo addition (Fig. 2B, Lower) . Insertion of the aptazyme per se resulted in somewhat reduced E1A expression, but importantly strong inhibition of E1A expression was achieved by theo addition (Fig. 2B, Upper) . Regulation by theo was best for the 5′3′ con struct, for which we also showed dose dependent regulation (Fig.  S2A) , and the least pronounced with the 5′ construct. To explore how the aptazyme mediated block of E1A expression translates into inhibition of viral DNA replication, we quantified viral ge nome copies during a single viral replication cycle (Fig. 2C) . For the Rz viruses, we observed a strong reduction of genome copy numbers compared with the control virus, which was 200 to 2,000 fold at 80 h postinfection (p.i.). For the Az viruses, we observed a minimal delay in DNA replication in absence of theo. Addition of theo resulted in minor, intermediate, and strong reduction of viral genome copy numbers for the Az 5′, 3′, and 5′3′ viruses, respectively, which was dose dependent (as shown for the Az 5′3′ virus; Fig. S2B ).
These results are in accord with the observed E1A protein ex pression profiles, validating virus replication as biological readout for aptazyme mediated gene regulation. Theo mediated regulation of viral replication of the Az 5′3′ virus at 80 h p.i. was approxi mately 200 fold. Overall, these results demonstrate that aptazyme insertion into both 5′ and 3′ UTRs of the viral E1A gene is suit able for conditional shutdown of viral gene expression, facilitating indirect control of viral DNA replication. In fact, potent inhibition of adenoviral DNA replication was achieved even using an apta zyme that possesses modest induction rates like P1 F5.
Aptazyme Shutdown of Adenoviral E1A Expression Inhibits Infectious
Virus Particle Production and Oncolysis. For applications as safety switch in the context of oncolytic viruses or virus vaccines, it is essential that aptazyme regulation of viral genes translates into inhibition of infectious viral particle production and spread dependent cytotoxicity. Indeed, infectious progeny production of the Az 5′3′ virus in SK MEL 28 cells was completely blocked in a dose dependent manner by theo at 48 h p.i. (Fig. 3A and Fig.  S2C ). At 80 h p.i., progeny viruses were produced in the presence of theo, but remained at approximately 60 fold lower titers than in the absence of theo. Titers of the Az 5′3′ virus in the absence of theo did not reach the titers of the control virus, indicating that aptazyme insertion per se resulted in some degree of attenuation, as expected from the E1A expression and virus genome replica tion data ( Fig. 2 B and C) . Note that the positioning of the aptazyme in the E1A UTRs was not optimized and it remains to be investigated whether insertion site optimization improves ad enovirus replication in the absence of the ligand. Infectious par ticle production of the control virus was not affected by theo and was completely inhibited for the Rz 5′3′ virus (Fig. 3A) .
Next, we investigated regulation of oncolytic activity of ade noviruses by the aptazyme. In a spread dependent cytotoxicity assay allowing for several rounds of virus replication (Fig. 3B) , we observed almost complete cell killing by the control virus without any insertion, but no loss in cell viability after infection with the Rz 5′3′ virus, both independently of theo. Importantly, for the Az 5′3′ virus, we observed cytotoxicity similar to the control virus in the absence of theo, but high cell viability in the presence of theo, establishing a switch from 10 to 80% viability. In conclusion, aptazyme insertion into the E1A gene resulted in effective ligand dependent control of infectious virus particle production and oncolytic activity of adenoviruses.
Flexible Shutdown of Adenoviral Infection by Aptazyme Regulation of E1A Expression. In the previous assays, theo was added to infected cell cultures immediately after infection. We next investigated whether established adenovirus infection can be switched off by using the aptazyme, resembling the application as a safety switch (Fig. 3C ). By quantification of viral genome copy numbers as readout for virus replication, we confirmed potent aptazyme dependent theo induced inhibition at 6, 9, and 12 d p.i. when theo was added immediately after infection. When adding theo at 6 d p.i., i.e., during full adenovirus replication, viral genome Our results demonstrate potent control of adenovirus replication by aptazyme regulation of E1A expression in SK MEL 28 cells using the P1 F5 aptazyme. When testing a panel of other tumor cell lines, we observed similar replication control in some cell lines. In Colo 829 melanoma and NCH89 glioblastoma cells, aptazyme mediated inhibition of viral genome replication after theo addition was similar to that using the ribozyme virus, demonstrating that our results are not restricted to SK MEL 28 melanoma cells (Fig. 3D) . However, regulation of virus genome amplification was not observed in A549 and Capan 1 cells (Fig.  S3A ). Importantly, this was not due to failure of the aptazyme to regulate E1A protein expression, because we could demonstrate theo dependent inhibition of E1A expression for the Az 5′3′ virus in both cell lines (Fig. S3B) . We hypothesized that this cell line dependent lack of replication control despite functional regulation of E1A expression must be due to a favorable cellular milieu for adenovirus replication and could be overcome in two ways: By improving aptazymes for increased self cleaving activity in presence of the ligand (this can only be addressed in the future once such aptazymes become available, see Discussion) or by reducing the baseline level of E1A expression. Toward this end, we could show for Capan 1 cells that replacing the E1A pro moter with weaker human promoters resulted in reduced E1A baseline expression (Fig. S3C ) and retained aptazyme mediated regulation of E1A expression (Fig. S3D) , thereby enabling aptazyme mediated inhibition of adenovirus replication as ana lyzed by viral genome amplification (Fig. S3E) and infectious virus progeny production (Fig. S3F) . Overall, these results clearly demonstrate the general applicability of aptazymes as safety switches for blocking adenovirus replication, although improved switches are required to establish the full potential of this approach.
Aptazyme Insertion into the Measles Virus Fusion Gene Results in Ligand-Dependent Shutdown of Gene Expression, Viral Infectivity, and Viral Spread. We next investigated whether applications of aptazymes for shutdown of viral gene expression can be extended to RNA viruses. Importantly, aptazyme activity has so far not been demonstrated in cytosolic RNA systems or in the context of RNA genomes. We used measles virus based on the Edmonston B vaccine strain (MV) as model virus (Fig. 1A) , because viruses derived from this strain are being clinically developed as onco lytic agents (1). We inserted the OFF switch aptazyme P1 F5 into the viral fusion (F) gene. The F protein mediates fusion of the viral and host cell membranes after virus attachment, resulting in viral entry into the cell. Furthermore, F proteins of infected cells trigger cell fusion with neighboring cells resulting in syncytia formation. We hypothesized that ligand induced ac tivation of the aptazyme results in degradation of the F mRNA and thus in loss of F protein expression, fusion activity, virus infectivity, and ultimately spread (Fig. 1B and Fig. S1B ). Note that in this setting, replication of the input viruses should not be affected, but rather infectivity of the progeny virus generation lacking F proteins. Regulating F protein expression has the technical advantage of allowing for validation of aptazyme mediated regulation in transient transfection studies using a fusion assay as readout.
To address our hypothesis, we inserted the P1 F5 aptazyme, the constitutively active ribozyme, or inactive mutants thereof (point mutation in the active center) into both 5′ and 3′ UTRs of the F gene, initially within an expression plasmid (Fig. 4A and Fig. S4A) . A control plasmid contained only the cloning sites. We could demonstrate ligand dependent inhibition of syncytia for mation for the 5′3′ aptazyme construct in a fusion assay (Fig.  S4B) . Here, F expression plasmids are transfected together with plasmids encoding the MV attachment protein H and GFP, yielding fluorescent syncytia when all proteins are expressed (30) . Results similar to the 5′3′ aptazyme construct were obtained with F expression plasmids containing only one apta zyme in either the 5′ or the 3′ UTR (Fig. S4B) . The ribozyme construct did not yield syncytia irrespective of the ligand, whereas the ribozyme and aptazyme mutants and the empty control constructs readily produced syncytia. These results in dicate that conditional expression of F by aptazyme regulation is functional and translates into control of syncytia formation.
We then produced viruses with F genes containing aptazymes (Azs) or inactive mutant aptazymes (inAzs) in both 5′ and 3′ UTRs (Fig. 4A) . The control virus contained the cloning sites in the UTRs. These viruses were generated at similarly high titers, whereas a virus with 5′3′ ribozyme insertions could not be res cued. The latter could also not be established when the F protein was complemented by F plasmid cotransfection, indicating that the nascent, unpackaged MV (+)RNA antigenome must be ef ficiently cleaved by the ribozyme after transfection of MV pro duction plasmids (31) . Infection studies in Vero and SK MEL 28 cells showed theo dependent shutdown of F protein expression for the Az 5′3′ virus (Fig. 4B) . In Vero cells, aptazyme insertion per se resulted in somewhat lower F protein expression. In SK MEL 28 cells, addition of theo alone had nonspecific effects on virus replication as deduced from reduction of both N and F proteins. Nevertheless, the specific aptazyme mediated control of F protein expression after infection with the Az 5′3′ virus was clearly visible. A comparison of F and N protein expression for the Az 5′3′ virus also indicates that aptazyme mediated regulation is at the mRNA level rather than by degradation of the (+)RNA antigenome during virus infection, as the latter would cause re duced secondary transcription from the replicated (−)RNA ge nome and, consequently, similar reduction of F and N protein levels. As newly synthesized (+)RNA antigenomic RNA mole cules are cotranscriptionally packaged, the MV nucleocapsid structure prevents proper folding of the aptazyme sequence as required for self cleavage activity.
Next, we analyzed how control of F expression translates into shutdown of MV infectivity using infectious particle production in a single step growth curve as readout based on the fact that the infectivity of the progeny particles essentially depends on F protein (Fig. 4C) . At 48 h after infection of Vero cells, we ob served a prominent, 11 fold reduction of infectious particle production after addition of theo specifically for the Az 5′3′ vi rus. In SK MEL 28 cells, we observed an 8 fold reduction of infectious particle production for the control and inAz 5′3′ virus after addition of theo, which was in line with the slight reduction of F and N protein expression (Fig. 4B) . However, 48 h p.i. re duction of infectious particle production by theo was 50 fold for the Az 5′3′ virus, confirming ligand dependent regulation via the aptazyme. Regulation was not observed for viruses containing single aptazymes in either the 5′ or the 3′ UTR of the F gene (Fig. S4C) . Syncytia formation was not affected by aptazyme regulation (Fig. S4D ), indicating that low amounts of newly generated F protein are sufficient to induce syncytia in a single step growth experiment.
Considering the aptazyme independent effects of 3 mM theo, we performed a dose response experiment showing that 1.5 mM theo facilitated effective aptazyme dependent regulation of MV infectivity, but lower nonspecific virus attenuation (Fig. 4D) . Consequently, theo resulted in superior regulation of infectious particle production at 1.5 mM compared with 3 mM. To better demonstrate how aptazyme shutdown of F expression leads to a block of MV infection and spread, we performed a multistep growth curve after low titer virus inoculation of SK MEL 28 cells. In this setting, measurement of the ultimately produced infectious particles depends on several rounds of infection for which functional F protein is required. Indeed, we observed a powerful inhibition of spread dependent infectious MV pro duction by theo for the Az 5′3′ virus, but not for the inAz 5′3′ virus (Fig. 4E) , thus establishing long term control of MV in fection. Here, aptazyme mediated shutdown of MV replication by theo was more potent at lower virus titers. In conclusion, these results demonstrate that aptazymes facilitate conditional knockdown of RNA virus genes translating into biological readouts, here ligand induced shutdown of MV spread.
Discussion
Our study shows that a model aptazyme enables small molecule triggered shutdown of DNA virus immediate early gene and RNA virus glycoprotein expression, resulting in inhibition of viral rep lication and infectivity, respectively, and consequently of viral spread and cytotoxicity. Conditional expression of the adenoviral gene E1A, the master regulator of adenoviral replication, was achieved with increasing efficiency by inserting the aptazyme into the 5′ UTR, 3′ UTR, or both UTRs. These data very well match our previously reported results for regulation of reporter genes, pointing at an universal applicability of aptazymes for gene regu lation (17) . Of note, insertion positions for the aptazyme within the UTRs were not optimized, revealing that interference of neighboring sequences with proper folding and activity of the aptazyme is not a major concern. A key question we addressed in this study was how small molecule triggered, aptazyme mediated regulation of viral gene expression as an input signal affects viral functions as biological output. Whereas single aptazyme insertion moderately affected viral replication, 5′3′ double insertion trans lated into a dramatic, dose dependent inhibition of adenoviral E558 genome replication, infectious particle production, and cytotoxic ity in SK MEL 28 cells. Corroborated by the maximal replication inhibition achieved with the constitutively active ribozyme, our results thus provide a proof of concept that aptazyme mediated regulation of viral gene expression can effectively affect viral functions. Importantly, we extended the applicability of aptazyme mediated regulation to RNA viruses and fully cytoplasmic gene expression systems: aptazyme mediated shutdown of F glycopro tein expression in Vero and SK MEL 28 cells translated into re duced infectivity of progeny viruses and a dramatic attenuation of virus spread in a multistep infection assay using SK MEL 28 cells.
Considering these results, we suggest aptazymes as novel tools for exploring virus gene functions in experimental infections and as a safety switch for new generations of efficiency enhanced oncolytic viruses. Careful analysis of our results, however, reveals several current limitations regarding the utilization of the P1 F5 aptazyme, which was the best available aptazyme at the time this study was initiated: (i) In line with our previous results (17) , aptazyme mediated shutdown of E1A was less effective than shutdown by the parental ribozyme, which executed maximal repression due to constitutive self cleavage activity. This pro vides proof of concept for the aptazyme approach as such, but implies that the P1 F5 aptazyme represents a suboptimal switch, clearly leaving a window of opportunity for improvement. (ii) In two of four further tested cell lines, A549 and Capan 1 cells, aptazyme mediated reduction of E1A expression did not trans late into shutdown of viral genome replication, although the ribozyme control virus was capable of replication shutdown in all tested cell lines. This input output disconnect likely results from a lower E1A input necessary to drive adenoviral replication or from higher E1A baseline expression in these cells. (iii) Simi larly, shutdown of glycoprotein F expression did not translate into inhibition of syncytia formation during primary measles vi rus infection, indicating that F protein at the observed reduced concentrations is sufficient to induce syncytia, while not sup porting infectivity of progeny viruses. However, results from an RNAi study demonstrate that effective down regulation of F protein expression translates into a lack of syncytia formation (32) . (iv) Baseline expression of regulated genes, i.e., in absence of the ligand, can be affected by aptazyme insertion to varying degrees. (v) Aptazyme activation by applying ligands to established infections allowed for replication control, but in a delayed fashion.
Essentially, all these issues can be addressed by optimizing the aptazyme for higher induction rates and thus improved gene shutdown potency. Clearly, the fact that the constitutively active ribozyme caused potent inhibition of virus replication in all cases indicates that the aptazyme approach should be universally functional with optimized aptazymes. Artificial aptazymes have been mostly developed in vitro and in bacteria, where aptazymes with high induction rates were generated by high throughput selection (12, 13, 20, 33) . However, only a few aptazymes have been reported to be functional in mammalian cells. The apta zyme P1 F5 used here was obtained by manual selection from only 192 aptazyme constructs with random communication sequences. Thus, it is very likely that high throughput selection of highly diverse libraries will yield new generations of high fidelity aptazymes. Optimized aptazymes should also be re sponsive to lower concentrations of theo, thus avoiding non specific effects on cell and virus behavior, as observed in this study. A key advantage of aptazymes is that they can be cus tomized to respond to alternative ligands. To this end, aptamers with high affinity for a diversity of small molecule ligands, e.g., for antibiotics like tetracycline, kanamycin, neomycin, and tobra mycin, have been reported (34) . Moreover, aptamers for further ligands of interest, ideally pharmaceuticals with known safety, bioavailability, and cell permeability profile, can be developed by affinity selection of RNA libraries (35) . These aptamers can then be exploited for the development of novel aptazymes. In this line, Smolke and coworkers have reported the custom ization of hammerhead ribozyme based aptazymes for regu lation of reporter genes and therapeutic genes by exchange of the theo aptamer domain with a tetracyclin aptamer (21, 25) . Yokobayashi and coworkers have recently reported a guanine inducible aptazyme featuring a 29.5 fold induction rate (36) . Comprehensive efforts of directed evolution of aptazymes in mammalian cells using high throughput techniques will eventu ally lead to the identification of optimized aptazymes, ultimately allowing for more effective regulation of biological outputs.
Several other aspects of our regulation system may be further improved in the context of basic research or therapeutic appli cations. First, the exact positions in the UTRs for the aptazyme insertion(s) should be systematically optimized to minimize reductions in baseline gene expression after aptazyme insertion possibly resulting from adverse effects on mRNA translation or stability independent of ligand induced aptazyme regulation. Second, adjustment of baseline viral gene expression levels can improve aptazyme control of biological outcomes, as concep tionally shown here for adenoviral E1A in control of viral in fection in Capan 1 cells using promoter modified viruses. Alternatively, adenoviral genes other than E1A that more di rectly link gene expression input to virus replication output can be regulated. In this context, the DNA polymerase or IVa2 genes could be of interest, as their knockdown RNAi proved more effective than that of E1A (37, 38) . Similarly, aptazyme regula tion of the measles virus P or L polymerase genes or of the nucleocapsid N gene may facilitate conditional virus replication, as indicated by RNAi studies (39, 40) . Finally, the pace of shutting down established virus infections can most certainly be accelerated considerably by combined control of several viral genes blocking viral infections simultaneously at different stages of the virus replication cycle.
For exploring virus gene functions in experimental infections, aptazymes offer key advantages compared with protein dependent inducible promoters (as discussed in the Introduction) and RNAi (41) . First, ligand induced regulation of gene expression by apta zymes functions in cis and is thus mechanistically likely to be more effective than RNAi regulation, although systematic comparisons will have to be performed to prove this assumption. Second, aptazyme mediated gene shutdown is induced by small molecule ligands that are less intrusive than nucleic acid transfection and should exert fewer nonspecific off target effects than siRNAs. Furthermore, small molecules as triggers allow for more precise timing of virus gene shutdown. Most importantly, in vivo appli cations of RNAi are hampered by delivery problems, whereas small molecules triggering aptazyme mediated shutdown of viral genes should be systemically available and thus facilitate in vivo studies investigating the role of genes in virus tropism, spread, pathogenicity, or immune escape.
The aptazyme regulation system presented in this study may find therapeutic application in conjunction with oncolytic viru ses. Although clinical trials have generally demonstrated the safety of present oncolytic viruses, they have also revealed that viruses with increased potency are required to establish thera peutic efficacy in patients (1, 4) . For such viruses, it is paramount to ensure safety. Considering the shortage of antiviral drugs, aptazymes might establish a necessary safety mechanism. Such safety switches are of interest for clinical development of certain candidate oncolytic viruses like Coxsackievirus A21 and vesicular stomatitis virus, that have shown potent antitumor activity, but also fatal toxicity in animal models (refs. 2, 3, and references therein). Note that in these cases promoter targeting is not possible due to their RNA genomes. Moreover, extensive re search efforts focus on enhancing the efficiency of established oncolytic viruses. Strategies toward this end include enhance ment of virus cell binding, improvement of virus spread, atten uation of IFN sensitivity, and insertion of therapeutic genes (1, 4) . Because it is often difficult to predict potential side effects of such modifications, e.g., resulting from infection of previously not susceptible cells by tropism modified viruses or from the induction of overshooting immune responses, clinical imple mentation of efficiency enhanced oncolytic viruses can benefit from or even require a safety switch. Lately, various cell types with intrinsic tumor tropism are being exploited as carrier cells for oncolytic virus delivery. Once infected, they protect the virus from the host's immune system during transport before releasing progeny particles at the tumor site (42) . In this context, transient aptazyme mediated inhibition of virus replication in carrier cells could improve their migration to the tumor and avoid premature release of progeny viruses, also adding to overall efficacy and safety of oncolytic viruses.
In summary, we establish artificial riboswitches as a novel tool for drug regulated expression of viral genes and resulting viral E560 functions. Regulation of adenoviral E1A and measles virus gly coprotein F enabled control of viral replication and spread. Importantly, aptazyme regulated gene expression was functional in the context of both DNA and RNA viruses and thus was shown to be fully active in cytoplasmatic systems. Hence, as an appealing alternative to protein and RNAi dependent gene regulation systems, we propose aptazymes as universally appli cable tools to study viral gene functions and to allow safety of new generations of efficiency enhanced oncolytic viruses.
Materials and Methods
Mammalian Cell Culture Maintenance. Human cell lines HEK293 (embryonic kidney), SK MEL 28 (malignant melanoma), Capan 1 (pancreatic cancer), A549 (lung adenocarcinoma), NCH89 (glioblastoma), and monkey cell line Vero (African green monkey kidney) were cultivated in Dulbecco's Modified Eagle's Medium (Invitrogen) supplemented with 10% (vol/vol) heat inactivated FBS (PAA), 100 IU/mL penicillin, and 100 μg/mL streptomycin (both from Invitrogen). The human cell line Colo 829 (malignant melanoma) was culti vated in RPMI 1640 medium supplemented as described above. Cells were grown at 37°C in a humidified atmosphere of 5% (vol/vol) CO 2 .
Cloning and Production of Adenoviruses. Nomenclature was used as follows: Rz, hammerhead ribozyme N107 (43); Az, theophylline dependent aptazyme P1 F5 (23) . The term "in" describes a mutated Az or Rz sequence harboring the A14G point mutation within the catalytic core of the Rz domain, which was reported to inactivate Rz self cleavage (43) . All cloning steps were conducted by applying standard molecular biology techniques. Oligonu cleotides were synthesized by Eurofins MWG Operon. Cloned plasmids were purified by standard anion exchange columns (Qiagen) and verified by DNA sequencing (GATC Biotech). Restriction enzymes were obtained from Fer mentas, DNA polymerase was obtained from BioCat.
For cloning of OAd (oncolytic adenovirus) Δ24E1A variants (Az 5′/3′/5′3′, Rz 5′/3′/5′3′), pCDNA 3.1(+) (Invitrogen) and pS Δ24E1A (pShuttle containing the adenoviral E1A gene with a 24 bp deletion and the E1B transcription unit) (44) were used as cloning vectors. For a schematic outline of the OAd Δ24E1A variants, see Fig. 2A . First, the E1A transcription unit was cloned into pCDNA 3.1(+) via SspI and KpnI. Then, Rz was inserted into pCDNA E1A by PCR into the 5′ or 3′ using primer pairs encoding the Rz sequence (5′ E1A N107 fw, CGAAACGCGCTTCGGTGCGTCCTGGATTCCACTGCTATCCA CTTCTCCTCCGAGCCGCTCC and 5′ E1A N107 rv, TCCTATTTGGGACTCGT CAGCTGGATGTACCTGCACCTCAGAACTCTACTCGCTGGCACTCAAG or 3′ E1A N107 fw, CGAAACGCGCTTCGGTGCGTCCTGGATTCCACTGCTATCCA CGTGTGGTTAACGCCTTTGTTTGC and 3′ E1A N107 rv, TCCTATTTGGGA CTCGTCAGCTGGATGTACCTGCACCTCAGACGCAATCACAGGTTTACACC). Then, Az (P1 F5) was introduced by PCR using primer pairs encoding the P1 F5 sequence (P1 F5 fw, AAGGCCCTTGGCAGGGTTCCTGGATTCCACTGCTATCCAC and P1 F5 rev, TCGGCTGGTATGGCTTTCGTCCTATTTGGGACTCGTCAG). For multimerization, pCDNA E1A Az 5′/Rz 5′ was combined with pCDNA E1A Az 3′/Rz 3′ via XbaI. Then, cloned pCDNA variants were subcloned into pS Δ24E1A via the unique restriction sites SspI and KpnI.
For cloning of OAd Δ24E1A promoter variants, wild type E1A promoter was replaced from position 343 524 (nucleotide positions refer to NCBI Se quence AC 000008.1) with the SV40 or TKs promoter insulated by a syn thetic polyA signal.
Subsequently, adenoviral particle variants were generated by homologous recombination in BJ5183 bacteria as described before (45) using the cloned pS Δ24E1A or pS Δ24E1A promoter variants and pAdEasy 1 (Promega).
Virus particle production, verification, and quantification were performed as previously described (17) . Quality of virus preparation was comparable as shown by similar ratios of physical virus particles to infectious virus particles: ctrl, 11; Az 5′, 4; Az 3′, 5; Az 5′3′, 6; Rz 5′, 10; Rz 3′, 11; Rz 5′3′, 13; SV40 ctrl, 15; SV40 5′3′, 14; TKs ctrl, 18; TKs 5′3′, 18; virus particle yield was in the same range for all OAd variants.
Cloning and Production of MVs. Nomenclature was used as described above. For cloning of MV EGFP F variants (ctrl, 5′3′, inAz 5′3′, Rz 5′3′, and inRz 5′3′), pCG F and pcpNSe ld EGFP (46) based on the Edmonston B vaccine lineage strain) were used as cloning vectors. For a schematic outline of the MV EGFP F variants, see Fig. 4A . First, restriction sites were inserted into the UTRs of the F gene according to the rule of six by site directed mutagenesis using primer pairs encoding the new restriction sites and spacer (pCG F HindIII rv, GAAAGCTTTTCTGGGATTCCCGGTGTC and pCG F BsrGI fw, GATCTGTACATC AAGACTCATCCAATGTCCATC or pCG F NheI rv, GCTAGCGAGTTGTAGAGG ATCAGAGCG and pCG F AflII fw, GATCGACTTAAGTTGAAACACAAATGTC CCACAAGTC). Upon combining both generated plasmids, the resulting pCG F HBNA plasmid (ctrl) was used as cloning vector for subsequent insertion of Rz or Az. Therefore, Rz or Az were amplified from psiCHECK 2 Rz or psiCHECK 2 Az (23) using various primer pairs for 5′ (Rz HindIII fw, GATCAAGCTTCT GAGGTGCAGGTACATCCAGC plus Rz C BsrGI rv, GATCTGTACAGGTGGATA GCAGTGGAATCCAGG or Az CC BsrGI rv, GATCTGTACAGGGTGGATAGCAGT GGAATCCAGG) and 3′ insertion (Rz NheI fw, GATCGCTAGCCTGAGGTGCA GGTACATCCAG plus Rz C AflII rv, GATCCTTAAGGGTGGATAGCAGTGGAATCC AGG or Az CC AflII rv, GATCCTTAAGGGGTGGATAGCAGTGGAATCCAGG). The resulting pCG F variants (pCG F Az/Rz 5′/3′/5′3') were then used for subcloning into pcpNSe ld EGFP. In brief, pCG F Az/Rz 5′/3′/5′3′ were digested with NarI and PacI and the F transcription unit was isolated and exchanged in pcpNSe ld EGFP via NarI and PacI. Generated pcpNSe ld EGFP F Az/Rz 5′/3′/5′3′ plasmids were sequence verified. Viral particles were produced according to a modified rescue system (47) . Vero cells were transfected with the respective pcpNSe based genomic plasmid and pCG N, pCG P, pCG L, and pcDI DsRed using FuGENEHD (Roche) reagent. The recombinant MV particles were amplified in Vero cells. Viral stocks from passage 3 were used for experiments, for verifi cation of viral genomes by RT PCR and PCR, and for sequencing of the F transcription unit. Virus titers were determined by titration on Vero cells [cell infectious units (ciu)/mL] as previously described (48). Virus particle yield was in the same range for all MV EGFP F variants. Immunoblot. For analysis of adenoviral E1A protein expression, infected cells were lysed in 100 μL radioimmunoprecipitation assay (RIPA) lysis buffer. In dicated amounts of total lysates were analyzed by immunoblot. E1A ex pression was determined by probing the membrane with a monoclonal antibody specific for adenoviral E1A protein (sc 25, clone M73; Santa Cruz Biotechnology).
For analysis of MV F protein expression, infected cells were lysed in 100 μL RIPA lysis buffer. Total lysates (40 μg) were analyzed by immunoblot. F ex pression was determined by probing the membrane with an anti F antibody. As internal infection control, N expression was determined by probing the membrane with an anti N antibody (32) (kind gifts from R. Cattaneo, Mayo Clinic, Rochester, MN).
Generally, equal loading was confirmed by using a mouse monoclonal antibody specific for human β actin (C4; MP Biomedical). Antibody binding was visualized using chemiluminescence (Pierce ECL, Thermo Fisher Scientific).
Quantitative PCR. For analysis of adenoviral genome copy numbers, DNA was purified using the QIAamp Blood Mini kit (Qiagen) following the manu facturer's instructions. Viral genome copy numbers were determined by quantitative real time PCR as previously described (17) using the 7300 Real Time PCR system (Applied Biosystems). Data were analyzed using the 7300 System SDS software (Applied Biosystems).
Infectious Progeny Production. To analyze the production of progeny viruses upon adenoviral infection, burst assays were performed. Infected cells were harvested with supernatant and after three freeze/thaw cycles, infectious viral particles were quantified by titration for infectious progenies in HEK293 cells. As internal control, infected cells were harvested 1 h p.i. and processed accordingly.
For analysis of infectious progeny production upon MV infection, burst assays were performed with one freeze/thaw cycle similar to the one for adenoviral infections described above. Here, harvested cells were titrated on Vero cells for produced infectious particles.
Cytotoxicity Assay. Virus spread dependent cytotoxicity was determined when cell lysis was visible at the lowest virus dilution using crystal violet staining as previously described (17) .
Fusion Assay. To confirm functionality of the cloned pCG F variants, fusion assays were performed. SK MEL 28 cells were cotransfected with respective pCG F variants, pCG H and pEGFP N1 (Clontech). As negative control, cells were transfected without pCG F. Transfected cells were subsequently cultured in the absence or presence of 3 mM theophylline. Phase contrast and fluorescence photos were taken 50 h posttransfection and merged (BIOREVO BZ 9000E; Keyence).
Statistical Analysis. All statistical analyses were performed of logarithmized data using GraphPad Prism 5.00 software (GraphPad Software). Differences between indicated groups were analyzed using two way ANOVA analysis of variance with Bonferroni posttest. Values of *P < 0.05, **P < 0.01, ***P < 0.001 were considered statistically significant.
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